Cover
Cover | Sep. 20, 2022 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | This Current Report on Form 8-K/A (this “8-K/A”) amends the Current Report on Form 8-K filed on September 26, 2022 (the “Earlier 8-K”) to correct typographical errors regarding (i) Mr. Culley’s current base annual salary amount from $690,000 to $609,000 and (ii) the manner of payment of cash severance benefits in the event of termination of employment without cause or by the executive with good reason. Except as to such corrections, this 8-K/A does not amend or update the information appearing in the Earlier 8-K. For convenience, the complete text of Item 5.02 of the Earlier 8-K, as corrected, is set out below. |
Document Period End Date | Sep. 20, 2022 |
Entity File Number | 001-12830 |
Entity Registrant Name | Lineage Cell Therapeutics, Inc. |
Entity Central Index Key | 0000876343 |
Entity Tax Identification Number | 94-3127919 |
Entity Incorporation, State or Country Code | CA |
Entity Address, Address Line One | 2173 Salk Avenue |
Entity Address, Address Line Two | Suite 200 |
Entity Address, City or Town | Carlsbad |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92008 |
City Area Code | (442) |
Local Phone Number | 287-8990 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common shares |
Trading Symbol | LCTX |
Security Exchange Name | NYSEAMER |
Entity Emerging Growth Company | false |
Entity Information, Former Legal or Registered Name | Not Applicable |